Artrya (ASX:AYA) Secures Cone Health In Five-Year SaaS Deal Is Its U.S. Beachhead Emerging?

Simply Wall St.

Dec 26, 2025

Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2594263302"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594263302\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594263302?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2025-12-26 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594263302","market":"nz","top_or_hot":-1,"title":"Artrya (ASX:AYA) Secures Cone Health In Five-Year SaaS Deal Is Its U.S. Beachhead Emerging?","media":"Simply Wall St.","content":"<div>\n<p>Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/artrya-asxaya-secures-cone-health-in-five-year-saas-deal-is\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artrya (ASX:AYA) Secures Cone Health In Five-Year SaaS Deal Is Its U.S. Beachhead Emerging?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtrya (ASX:AYA) Secures Cone Health In Five-Year SaaS Deal Is Its U.S. Beachhead Emerging?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-26 04:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/artrya-asxaya-secures-cone-health-in-five-year-saas-deal-is><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/artrya-asxaya-secures-cone-health-in-five-year-saas-deal-is\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AYA","symbol_name":"Amaya Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/artrya-asxaya-secures-cone-health-in-five-year-saas-deal-is","article_id":"2594263302","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-aya/artrya-shares/news/artrya-asxaya-secures-cone-health-in-five-year-saas-deal-is","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594263302","pubTimestamp":1766694313,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s network, securing its third commercial customer in the United States.\nThis latest deal completes the conversion of all three of Artrya’s U.S. foundation partners, signalling growing clinical adoption and a deeper foothold in the competitive American cardiac imaging market.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AYA":"Amaya Inc.","AYA.AU":"ARTRYA LTD","BK7094":"医疗保健技术"},"translate_title":"Artrya(ASX：AYA)在SaaS五年协议中获得Cone Health其美国滩头阵地正在出现吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYA.AU":1.5,"AYA":1.5},"content_text":"Artrya Limited recently announced a five-year SaaS agreement with U.S. healthcare provider Cone Health to roll out its Salix Coronary Anatomy and Plaque AI imaging modules across the health system’s network, securing its third commercial customer in the United States. This latest deal completes the conversion of all three of Artrya’s U.S. foundation partners, signalling growing clinical adoption and a deeper foothold in the competitive American cardiac imaging market. We’ll now examine how securing Cone Health as a long-term SaaS customer shapes Artrya’s investment narrative and future growth pathway. AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.What Is Artrya's Investment Narrative?To own Artrya, you need to believe its Salix platform can convert early regulatory wins into durable, recurring SaaS revenue before the company runs short of capital. The new five-year Cone Health agreement matters here: it helps validate product-market fit in the U.S., supports the idea that foundation partnerships can mature into commercial deals, and may become a reference point for further hospital contracts. In the short term, that strengthens the main catalysts around U.S. rollouts and utilisation of the Coronary Anatomy and Plaque modules, especially after FDA clearances. At the same time, revenue remains tiny at A$28,000 against losses of A$16.41 million and recent share price gains have been very large, so funding needs, dilution risk and execution by a relatively new management team still sit at the centre of the investment debate. However, investors should also weigh how recent capital raisings and rapid price gains affect the risk-reward.\n\nThe analysis detailed in our Artrya valuation report hints at an inflated share price compared to its estimated value.Exploring Other PerspectivesASX:AYA 1-Year Stock Price Chart Four Simply Wall St Community fair value views span about A$0.00 to A$3.06, showing wide disagreement. Set that against Artrya’s tiny revenue base, heavy losses and reliance on successful U.S. SaaS adoption.Explore 4 other fair value estimates on Artrya - why the stock might be worth as much as A$3.06!Build Your Own Artrya NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Artrya research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free Artrya research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Artrya's overall financial health at a glance.No Opportunity In Artrya?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.Uncover the next big thing with financially sound penny stocks that balance risk and reward.These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}